NCT06222801 The 1st Tumor CytokinoTherapy Database (TCTD-1)
| NCT ID | NCT06222801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | OncoCareClinic 308 Ltd |
| Condition | Oncology |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-09-19 |
| Primary Completion | 2032-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-09-19 with a primary completion date of 2032-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Predicting the response of patients diagnosed with cancer to cytokinotherapy is essential to guide anti-tumor therapy complex strategy and subsequent adjuvant approach. Cytokinotherapy is a cost-effective, well-known available method of therapy for the patients with tumors. The objective response possibly correlates to the tumor's size, aggressiveness, age, and other primary factors. Multifactor analysis requires a large amount of data. Therefore, the investigators created the first database aimed to collect data concerning the patients with cancer and the clinical outcomes of cytokinogenetic therapy. The acquired data must be processed to detect the key factors effecting the outcomes. Cytokinotherapy is a universal therapeutic approach, although we lack information that would help to personalize it and reduce the rate of progression. The main goal is to find the relationship between initial patients' characteristics and effectiveness of cytokinotherapy for early risks detection. The predictive models that could be elaborated from the TCTD-1 analysis will complement knowledge of cytokinotherapy rationale. Predicting survival or other significant clinical criteria using TCTD-1 analysis results would greatly benefit the cancer patients' management.
Eligibility Criteria
Inclusion Criteria: * adult patients aged 18 years or older with cancer who do not meet exclusion criteria, applied to the OncoCare308 Clinic Ltd. hospital for cytogenetic therapy, and are eligible to complete or have completed at least one course of cytogenetic therapy, as determined by the site. Exclusion Criteria: * Patients under 18 or over 95 years * Patients with hematologic cancer or thyroid tumors * Patients with contraindications for cytogenetic therapy * Patients who die before the start of therapy or before the first course completeness * Patients who do not sign the informed consent to be enrolled under the clinical observation in the hospital
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06222801 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 95 Years, studying Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06222801 currently recruiting?
Yes, NCT06222801 is actively recruiting participants. Contact the research team at info@oncocareclinic.ru for enrollment information.
Where is the NCT06222801 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT06222801 clinical trial?
NCT06222801 is sponsored by OncoCareClinic 308 Ltd. The trial plans to enroll 5,000 participants.